Weekly Pharma News Review | PharmaSources.com (Feb.6th - 10th, 2023)
A new indication of Pfizer's tofacitinib sustained release tablet was approved in China; Phase III study of obesity indication of Eli Lilly's Tirzepatide succeeded in China.
February 13, 2023
by Caicai
Free EDC software for non-profit COVID-19 related studies
Italy-based EDC provider, Nubilaria srl, offers its ACTide EDC pro-bono for European non-profit COVID-19 Coronavirus related studies.
March 20, 2020
by worldpharmanews
Takeda maintenance data set up Ninlaro for new myeloma nod
Takeda’s Ninlaro has watched from the sidelines as competing multiple myeloma drugs jumped into additional indications. But now it may finally be ready to do the same.
December 5, 2018
by fiercepharma
ASH: Can Johnson & Johnson sell regulators on Xarelto as clot prevention for cancer patients?
Johnson & Johnson's clot-busting Xarelto may not have hit the primary goal in its latest trial, but the company still believes it can win a new approval down the line—and as the drug's laundry list of current indications shows...
December 5, 2018
by fiercepharma
ASH: Johnson & Johnson's fast-growing Darzalex lines up for 2nd front-line myeloma OK
Johnson & Johnson’s Darzalex made multiple myeloma history this May when it became the first monoclonal antibody to score an FDA approval in newly diagnosed patients. And now, it’s looking to make it a repeat.
December 5, 2018
by fiercepharma
Clinical Data Management Leaders Reveal Underlying Challenges Impacting Trial Timelines
At the upcoming DIA 2018 Annual Meeting, Tufts Center for the Study of Drug Development (CSDD) will preview its study findings on the root causes for delays and inefficiencies impacting trial timelines.
June 27, 2018
by americanpharmaceuticalreview